Publications by authors named "A M Sardesai"
Genetic studies in Escherichia coli have implicated the unphosphorylated version of PtsN (unphospho-PtsN), the terminal phospho-acceptor of the PtsP-PtsO-PtsN phosphorelay, as a negative regulator of potassium (K) efflux mediated by YcgO. YcgO is a protein belonging to the CPA1 family of monovalent cation/proton antiporters. Here we show that in vivo, YcgO comprises an approximately 383 amino acid N-terminal transmembrane domain (TMD) and a 195 amino acid C-terminal cytoplasmic region (CTR).
View Article and Find Full Text PDFArticle Synopsis
- Targetoid hemosiderotic hemangioma is a rare, benign skin condition mostly seen in people in their 20s, typically affecting the trunk and lower limbs.
- It presents as a distinctive violaceous papule surrounded by a pale area and an ecchymotic ring, resembling a target.
- A case study describes a 23-year-old male with a recurring blue-black lesion on his shoulder, diagnosed as targetoid hemosiderotic hemangioma based on dermoscopic patterns.
Article Synopsis
- Irritable bowel syndrome (IBS) affects many medical students, with this study aiming to assess its prevalence and associated factors among students at Kasturba Medical College in India.
- Out of 397 participants, 16.9% were identified as likely having IBS, with a notable higher incidence in females (20.8%) compared to males (11.4%).
- The study found that IBS prevalence was higher among NRI students (28.6%) and those on a predominantly vegetarian diet (19.1%), while those living at home reported lower rates (14.5%).
In E. coli K-12, the absence of unphosphorylated PtsN (unphospho-PtsN) has been proposed to cause an L-leucine-sensitive growth phenotype (Leu) by hyperactivated K uptake mediated impairment of the expression of the ilvBN operon, encoding subunits of the L-valine (Val)-sensitive acetohydroxyacid synthase I (AHAS I) that renders residual AHAS activity susceptible to inhibition by Leu and K. This leads to AHAS insufficiency and a requirement for L-isoleucine (Ile).
View Article and Find Full Text PDFArticle Synopsis
- RSV significantly impacts infants in Spain, leading to many healthcare visits and high costs during their first RSV season.
- A decision-analytic model showed that using nirsevimab as a preventive treatment for all infants could dramatically reduce RSV-related health events and hospitalizations, compared to standard practices.
- Immunizing with nirsevimab could prevent over 97,000 outpatient visits and save about €47.8 million in healthcare costs, highlighting its potential as a cost-effective public health strategy.